Edition:
India

CSPC Pharmaceutical Group Ltd (1093.HK)

1093.HK on Hong Kong Stock

8.17HKD
30 Oct 2020
Change (% chg)

HK$-0.27 (-3.20%)
Prev Close
HK$8.44
Open
HK$8.35
Day's High
HK$8.44
Day's Low
HK$8.04
Volume
75,294,558
Avg. Vol
59,413,928
52-wk High
HK$11.35
52-wk Low
HK$6.83

Summary

Name Age Since Current Position

Dongchen Cai

66 2010 Executive Chairman of the Board, Chief Executive Officer

Cuilong Zhang

51 2019 Executive Vice Chairman of the Board, Rotating Chief Executive Officer

Kin Man Chak

54 2005 Executive Director

Chunlei Li

43 2017 Executive Director

Weidong Pan

50 2019 Executive Director

Huaiyu Wang

57 2010 Executive Director

Qingxi Wang

54 2018 Executive Director

Zhenguo Wang

50 2019 Executive Director

Ka Sze Lee

60 2004 Company Secretary, Non-Executive Director

Siu Keung Chan

62 2004 Independent Non-Executive Director

Chuan Chen

56 2016 Independent Non-Executive Director

Yuk Lam Lo

71 2014 Independent Non-Executive Director

Bo Wang

60 2012 Independent Non-Executive Director

Jinming Yu

62 2014 Independent Non-Executive Director

Biographies

Name Description

Dongchen Cai

Mr. Dongchen Cai serves as Executive Chairman of the Board, Chief Executive Officer of the Company. Mr. Cai was appointed as an executive director of the Company in 1998. Mr. Cai is also the chairman of the Nomination Committee of the Company and a director of certain subsidiaries of the Group. Mr. Cai holds a MBA degree from Nankai University and has extensive technical and management experience in the pharmaceutical industry. Mr. Cai is a substantial shareholder of the Company within the meaning of Part XV of the Securities and Futures Ordinance (“SFO”). Mr. Cai is also a director of True Ally Holdings Limited and Massive Giant Group Limited, both are substantial shareholders of the Company within the meaning of Part XV of the SFO.

Cuilong Zhang

Mr. Zhang Cuilong is Executive Vice Chairman of the Board, Rotating Chief Executive Officer of the Company. Mr. Zhang was appointed as an executive director of the Company in 2018. Mr. Zhang is also a director of certain subsidiaries of the Group. Mr. Zhang holds a bachelor’s degree in pharmacology from Hebei Medical College (now known as Hebei Medical University) and has extensive technical, marketing and management experience in the pharmaceutical industry.

Kin Man Chak

Mr. Kin Man Chak serves as Executive Director of the Company. Mr. Chak Mr. Chak is also a director of certain subsidiaries of the Group. Mr. Chak is a certified public accountant of the Hong Kong Institute of Certified Public Accountants and a fellow member of the Association of Chartered Certified Accountants. Mr. Chak holds a bachelor of social sciences degree from The University of Hong Kong and has extensive experience in finance, accounting and investor relations. Mr. Chak is a director of Common Success International Limited, a substantial shareholder of the Company within the meaning of Part XV of the SFO.

Chunlei Li

Mr. Li Chunlei is Executive Director of the Company. Dr. Li is currently the Chief Scientist of the Group in charge of research and development. Dr. Li is also the general manager of a subsidiary of the Company, deputy director of the Novel Pharmaceutical Preparations and Excipients State Key Laboratory and director of the Hebei Pharmaceutical Engineering Technology Centre. Dr. Li holds a bachelor’s degree in engineering (biological pharmaceutics) from Jilin University and Shenyang Pharmaceutical University, a master’s degree in science (microbial and biochemical pharmaceutics) from Jilin University and a doctorate in science (pharmaceutical science) from Shenyang Pharmaceutical University.

Weidong Pan

Mr. Weidong Pan is an Executive Director of the Company. Mr. Pan is also a director of certain subsidiaries of the Group. Mr. Pan holds an EMBA degree from Tsinghua University and has extensive finance, accounting and investment experience in the pharmaceutical industry. Mr. Pan is a director of Common Success International Limited, a substantial shareholder of the Company within the meaning of Part XV of the SFO.

Huaiyu Wang

Mr. Wang Huaiyu is Executive Director of the Company. Mr. Wang is also a director of certain subsidiaries of the Group. Mr. Wang holds a bachelor’s degree in microbiology and biochemistry from Hebei University and has extensive technical and management experience in the pharmaceutical industry.

Qingxi Wang

Dr. Wang Qingxi serves as Executive Director of the Company. Dr. Wang is also a director of certain subsidiaries of the Group. Prior to joining the Group, Dr. Wang worked at Merck & Co., Inc. in the U.S. for 20 years where he held senior positions including director of pharmaceutical R&D and director of business development and operation. Dr. Wang holds a bachelor’s degree in science (chemistry) and a master’s degree in science (chemistry) from Nankai University in China, a master’s degree in science (polymer science) and a doctorate in chemistry from University of Connecticut in the U.S. and a MBA degree from Temple University in the U.S..

Zhenguo Wang

Mr. Wang Zhenguo is Executive Director of the Company. Mr. Wang is also a director of certain subsidiaries of the Group. Mr. Wang holds a bachelor’s degree in chemistry from Nankai University and has extensive technical, marketing and management experience in the pharmaceutical industry.

Ka Sze Lee

Mr. Ka Sze Lee CPA serves as Company Secretary, Non-Executive Director of the Company. He was appointed as a non-executive director in 1996, re-designated as an independent nonexecutive director in 1998 and further re-designated as a non-executive director in 2004. Mr. Lee is also a member of the Audit Committee and Remuneration Committee and the Company Secretary of the Company. Mr. Lee holds a bachelor of laws degree from The University of Hong Kong. Mr. Lee is a practising solicitor and a partner of Woo, Kwan, Lee & Lo. Mr. Lee is also a non-executive director of Safety Godown Company Limited and Playmates Holdings Limited (appointed on 5 November 2019) and an independent non-executive director of KWG Property Holding Limited, Esprit Holdings Limited and China Pacific Insurance (Group) Co., Ltd.. Mr. Lee resigned as a non-executive director of Yugang International Limited and Hopewell Holdings Limited on 30 April 2019 and 3 May 2019 respectively and retired as a non-executive director of Termbray Industries International (Holdings) Limited on 13 September 2019. All of the above companies are listed on the Stock Exchange of Hong Kong Limited. Mr. Lee is a chairman of the Listing Review Committee of The Stock Exchange of Hong Kong Limited, a convenor cum member of the Financial Reporting Review Panel of the Financial Reporting Council, a chairman of the Appeal Tribunal Panel Constituted under the Building Ordinance and a member of the InnoHK Steering Committee.

Siu Keung Chan

Mr. Chan Siu Keung is Independent Non-Executive Director of the Company. Mr. Chan is also the chairman of the Audit Committee and Remuneration Committee and a member of the Nomination Committee of the Company. Mr. Chan is a qualified accountant and a member of the Institute of Chartered Accountants of Ontario. Mr. Chan holds a master of business administration degree from York University, Ontario, Canada and has extensive experience in finance and investment.

Chuan Chen

Mr. Chen Chuan is Independent Non-Executive Director of the Company. Mr. Chen holds a bachelor’s degree in Medicine from Norman Bethune University of Medical Science and a Master’s degree in Science from Albert Einstein College of Medicine at Yeshiva University. Mr. Chen is also a director of Beijing Dong Fang Ming Kang Medical Equipment Co., Ltd. (quoted on the National Equities Exchange and Quotations System), a director of Shanghai Benemae Pharmaceutical Corporation (quoted on the National Equities Exchange and Quotations System) and an independent director of Guangxi Liuzhou Pharmaceutical Co., Ltd. (listed on Shanghai Stock Exchange).

Yuk Lam Lo

Prof. Yuk Lam Lo serves as Independent Non-Executive Director of the Company. He is also a member of the Nomination Committee of the Company. Prof. Lo is currently the Chairman of the Advisory Council on Food and Environmental Hygiene of the Food and Health Bureau of the HKSAR Government, Founding President of HK Bio-Med Innotech Association, Honorary Founding Chairman of Hong Kong Biotechnology Organization, Honorary Chairman of Hong Kong Food Safety Association and a Committee Member of the Chinese Manufacturers’ Association of Hong Kong. Prof. Lo is an Honorary Fellow of the Hong Kong University of Science and Technology, Adjunct Professor of the Chinese University of Hong Kong and Honorary Professor of several universities in China. Prof. Lo was heavily involved in several committees of the HKSAR Government. He had been appointed as Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund

Bo Wang

Mr. Bo Wang serves as Independent Non-Executive Director of the Company. He is also a member of the Audit Committee and Remuneration Committee of the Company. Mr. Wang is currently the CEO of Beijing CHNMED Pharmaceutical Technology Development Co., Ltd and managing director of Beijing CHNMED Pharmaceutical Consulting Co., Ltd.. Mr. Wang graduated from Beijing Institute of Iron and Steel and has extensive experience in pharmaceutical policy research and consulting. Mr. Wang is currently the distinguished researcher of the Research Center of National Drug Policy & Ecosystem. Mr. Wang is also an independent director of Henan Taloph Pharmaceutical Stock Co., Ltd. (listed on Shanghai Stock Exchange) and Jiuzhitang Co., Ltd. (listed on Shenzhen Stock Exchange).

Jinming Yu

Dr. Jinming Yu serves as Independent Non-Executive Director of the Company. Dr. Yu is an Academician of Chinese Academy of Engineering, and is currently the Honorary President of Shandong Academy of Medical Sciences and the President of Shandong Cancer Hospital. Dr. Yu holds a bachelor’s degree in medicine from Changwei Medical College and a doctorate in radiology from Shandong University.

Basic Compensation

Name Fiscal Year Total

Dongchen Cai

12,149,000

Cuilong Zhang

6,527,000

Kin Man Chak

4,857,000

Chunlei Li

4,779,000

Weidong Pan

3,906,000

Huaiyu Wang

3,890,000

Qingxi Wang

2,735,000

Zhenguo Wang

6,090,000

Ka Sze Lee

334,000

Siu Keung Chan

238,000

Chuan Chen

106,000

Yuk Lam Lo

106,000

Bo Wang

106,000

Jinming Yu

88,000
As Of  31 Dec 2019